# RASGRP3

## Overview
RASGRP3 (RAS guanyl releasing protein 3) is a gene that encodes a guanine nucleotide exchange factor (GEF) protein involved in the activation of the RAS signaling pathway. The RASGRP3 protein plays a pivotal role in cellular processes such as proliferation, differentiation, and survival by facilitating the exchange of GDP for GTP on RAS proteins. This protein is predominantly active in the cytoplasm and is crucial for immune cell signaling, particularly in B and T lymphocytes, where it influences immune responses and development (Zeng2014Upregulation). RASGRP3 is notably expressed in B cells, where it participates in B cell receptor (BCR) signaling pathways, essential for modulating immune responses (Golinski2015Dysregulation). Additionally, RASGRP3 is implicated in various pathological conditions, including cancer, where it acts as an oncogenic effector in the Ras/MAPK pathway, contributing to tumor progression and treatment resistance (Nagy2014Function; Chen2017RasGRP3).

## Function
RASGRP3 (RAS guanyl releasing protein 3) is a guanine nucleotide exchange factor (GEF) that plays a critical role in activating the RAS signaling pathway by facilitating the exchange of GDP for GTP on RAS proteins. This activation is essential for various cellular processes, including cell proliferation, differentiation, and survival. RASGRP3 is primarily active in the cytoplasm and is involved in immune cell signaling, particularly in B and T lymphocytes, influencing immune responses and development (Zeng2014Upregulation).

In healthy human cells, RASGRP3 is preferentially expressed in B cells, where it is involved in B cell receptor (BCR) signaling pathways. These pathways are crucial for B cell function and immune response modulation (Golinski2015Dysregulation). The expression of RASGRP3 in B cells is significantly higher than in T cells, and its expression can be modulated by TNFα, a pro-inflammatory cytokine. TNFα increases RASGRP3 mRNA and protein expression levels in B cells, suggesting its role in inflammation and immune response (Golinski2015Dysregulation).

While the specific functions of RASGRP3 in healthy human cells are not extensively detailed, its involvement in B cell signaling and immune response highlights its importance in maintaining normal immune function (Golinski2015Dysregulation).

## Clinical Significance
RASGRP3 is implicated in the progression and treatment resistance of several cancers due to its role in the Ras signaling pathway. In breast cancer, particularly invasive ductal adenocarcinoma, RASGRP3 is overexpressed, contributing to increased cell proliferation and survival. Its down-regulation in breast cancer cell lines like MCF7 and T-47D results in reduced tumor growth, increased apoptosis, and enhanced sensitivity to chemotherapeutic agents such as tamoxifen and trastuzumab (Nagy2014Function). This suggests that RASGRP3 could be a potential therapeutic target in breast cancer treatment.

In prostate cancer, RASGRP3 expression is associated with aggressive cancer characteristics and poorer survival outcomes. It is upregulated in a significant portion of prostate cancer tissues and correlates with higher Gleason scores and advanced tumor stages. Knockdown of RASGRP3 in prostate cancer cell lines leads to decreased proliferation, migration, and invasion, indicating its role as an oncogene in this context. RASGRP3 expression is also linked to increased risk of PSA recurrence after radical prostatectomy, making it a potential prognostic biomarker for aggressive prostate cancer (Zeng2014Upregulation).

These findings highlight the clinical significance of RASGRP3 in cancer progression and its potential as a target for therapeutic intervention.

## Interactions
RASGRP3 interacts with several proteins and plays a significant role in various cellular signaling pathways. It is known to activate the small GTPase Rap1, which is crucial for regulating inflammatory responses in macrophages. This interaction leads to the inhibition of proinflammatory cytokine production, such as IL-6 and TNFa, by negatively regulating TLR-triggered inflammatory responses (Tang2014RasGRP3). 

In the context of cancer, RASGRP3 is involved in the activation of the Ras/MAPK pathway, particularly in uveal melanoma with GNAQ mutations. It acts as an oncogenic effector and transcriptional target downstream of GNAQ/11, contributing to MAPK pathway activation (Chen2017RasGRP3). In breast cancer, RASGRP3 modulates the expression of IGF-I and EGF receptors and interacts with diacylglycerol (DAG) and phorbol esters, which regulate its translocation and activity. It also interacts with dynein light chain 1 (DLC1), influencing its subcellular localization and potentially facilitating nuclear translocation (Nagy2014Function).

RASGRP3 also influences the expression of EMT-related proteins in esophageal squamous cell carcinoma, affecting proteins such as E-cadherin and vimentin, and is associated with the Notch signaling pathway (Hu2017Novel).


## References


[1. (Golinski2015Dysregulation) Marie-Laure Golinski, Thibault Vandhuick, Céline Derambure, Manuel Fréret, Matthieu Lecuyer, Clément Guillou, Martine Hiron, Olivier Boyer, Xavier Le Loët, Olivier Vittecoq, and Thierry Lequerré. Dysregulation of rasgrp1 in rheumatoid arthritis and modulation of rasgrp3 as a biomarker of tnfα inhibitors. Arthritis Research &amp; Therapy, December 2015. URL: http://dx.doi.org/10.1186/s13075-015-0894-9, doi:10.1186/s13075-015-0894-9. This article has 15 citations.](https://doi.org/10.1186/s13075-015-0894-9)

[2. (Hu2017Novel) Ge Hu, Yuepeng Zhou, Yu Zhu, Ling Zhou, Rui Ling, Dan Wu, Lei Mi, Xuefeng Wang, Dongfang Dai, Chaoming Mao, and Deyu Chen. Novel transduction of nutrient stress to notch pathway by rasgrp3 promotes malignant aggressiveness in human esophageal squamous cell carcinoma. Oncology Reports, 38(5):2975–2984, September 2017. URL: http://dx.doi.org/10.3892/or.2017.5996, doi:10.3892/or.2017.5996. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2017.5996)

[3. (Nagy2014Function) Zsuzsanna Nagy, Ilona Kovács, Miklós Török, Dezső Tóth, György Vereb, Krisztina Buzás, István Juhász, Peter M Blumberg, Tamás Bíró, and Gabriella Czifra. Function of rasgrp3 in the formation and progression of human breast cancer. Molecular Cancer, April 2014. URL: http://dx.doi.org/10.1186/1476-4598-13-96, doi:10.1186/1476-4598-13-96. This article has 21 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/1476-4598-13-96)

[4. (Tang2014RasGRP3) Songqing Tang, Taoyong Chen, Zhou Yu, Xuhui Zhu, Mingjin Yang, Bin Xie, Nan Li, Xuetao Cao, and Jianli Wang. Rasgrp3 limits toll-like receptor-triggered inflammatory response in macrophages by activating rap1 small gtpase. Nature Communications, August 2014. URL: http://dx.doi.org/10.1038/ncomms5657, doi:10.1038/ncomms5657. This article has 45 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms5657)

[5. (Chen2017RasGRP3) Xu Chen, Qiuxia Wu, Philippe Depeille, Peirong Chen, Sophie Thornton, Helen Kalirai, Sarah E. Coupland, Jeroen P. Roose, and Boris C. Bastian. Rasgrp3 mediates mapk pathway activation in gnaq mutant uveal melanoma. Cancer Cell, 31(5):685-696.e6, May 2017. URL: http://dx.doi.org/10.1016/j.ccell.2017.04.002, doi:10.1016/j.ccell.2017.04.002. This article has 109 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.ccell.2017.04.002)

[6. (Zeng2014Upregulation) X Zeng, Z Hu, Z Wang, J Tao, T Lu, C Yang, B Lee, and Z Ye. Upregulation of rasgrp3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 17(2):119–125, January 2014. URL: http://dx.doi.org/10.1038/pcan.2013.51, doi:10.1038/pcan.2013.51. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/pcan.2013.51)